drugset / Trial / NCT04173533

Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT

NCT04173533

Phase 3 Unknown 326 enrolled University of Birmingham
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate a new maintenance therapy with the aim of improving the outcome of patients with acute myeloid leukaemia (AML) and myelodysplasia (MDS) after stem cell transplantation.

Timeline

Start
2019-06-14
Primary completion
2025-04
Completion
2025-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified 200 mg Oral